Dermsquared’s Post

I am privileged to share our new article published in the American Journal of Clinical Dermatology, which focuses on the use of topical calcineurin inhibitors on atopic dermatitis patients among the Taiwanese population. Please feel free to discuss and share your comments with me! https://lnkd.in/gYnFpfMh #atopicdermatitis #cohortstudy #topicalcalcineurininhibitors #NationalHealthinsuranceResearchDatabase

📚 Would you like to access the latest dermatology news? 📚 Discover our medical reviews on Ask NAOS Pro 👇 https://lnkd.in/dKjMgYZZ The medical reviews offer privileged access to scientific information from international events dedicated to dermatology 🎉 They are a summary of: • Our symposia held during the latest WCD2027, IMCAS, and European Academy of Dermatology and Venereology • Our e-symposia organized in cooperation with the University of Brescia, dedicated to Onco-Dermatology • Meetings of the European Society for Photodermatology, giving an overview of the main topics presented during the previous World Photodermatology Days. #Atopy #Hyperpigmentation #Oncology #Aging #Photoprotection #Photodermatology  

New Publication in Dermatology and Therapy: The analysis of an IL-13 inhibitor across EASI body regions and clinical signs of Atopic Dermatitis, results from ADvocate 1 & ADvocate 2 trials. View the full publication here: https://e.lilly/4ayAaKR

Today we presented positive data from a Phase 2 clinical trial of ESK-001, a highly selective allosteric TYK2 inhibitor, for the treatment of plaque #psoriasis at the American Academy of Dermatology Annual Meeting. Learn more: https://lnkd.in/e9pKPCBM #AAD2024

Lots of exciting developments in #psoriasis #psoriaticarthritis #lupus to follow. I guess that's why #venturecapital investing $250M+ here. #clinicaltrials #arthritis #medicine #heathcare

☀️ July is UV Safety Month! ☀️ Did you know that UV rays are the root cause of most skin cancers? The American Academy of Dermatology (AAD) recommends that you practice sun safety all year round. Learn how: https://lnkd.in/eczHxHyk

Ida Vittrup Nielsen, MD and PhD, Department of Dermatology, Bispebjerg Hospital, Denmark, discusses a cross-sectional study on risk factors, presented at EADV 2023, that could affect the use of JAK-inhibitors in Danish patients with atopic dermatitis. The results reveal the prevalence of various risk factors among the patient population and how they influence the choice of JAK-inhibitor treatment. #EADV23 #JAK #AtopicDermatitis

Now available: New congress report from the 32nd European Academy of Dermatology and Venereology 2023 Congress (#EADV)! In this report, 2022 IPC Fellow Juul van den Reek has compiled thirteen summaries of the latest and most inspiring presentations on psoriasis at this year’s EADV, including IPC’s symposium and late-breaking sessions. Read the summary or download the full report: https://lnkd.in/g_wx63ZU #IPCCongressReport #PsoriasisNews

Now available: New congress report from the 32nd European Academy of Dermatology and Venereology 2023 Congress (#EADV)! In this report, 2022 IPC Fellow Juul van den Reek has compiled thirteen summaries of the latest and most inspiring presentations on psoriasis at this year’s EADV, including IPC’s symposium and late-breaking sessions. Read the summary or download the full report: https://lnkd.in/g_wx63ZU #IPCCongressReport #PsoriasisNews

Access to biologic therapies is a critical issue in dermatology. We're thrilled to share Jason Zemcik's article from the latest edition of Access Dermatology Magazine, discussing key trends and solutions. Thank you for your contributions, Jason! Read more in our latest issue. ⬇️ #PatientAccess #Dermatology #Biologics #BCOD